Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Depreciation and Depletion (2016 - 2023)

Historic Depreciation and Depletion for Ekso Bionics Holdings (EKSO) over the last 11 years, with Q1 2023 value amounting to $414000.0.

  • Ekso Bionics Holdings' Depreciation and Depletion rose 7922.08% to $414000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $669000.0, marking a year-over-year increase of 45.05%. This contributed to the annual value of $658000.0 for FY2024, which is 936.64% down from last year.
  • As of Q1 2023, Ekso Bionics Holdings' Depreciation and Depletion stood at $414000.0, which was up 7922.08% from -$146000.0 recorded in Q4 2022.
  • In the past 5 years, Ekso Bionics Holdings' Depreciation and Depletion ranged from a high of $414000.0 in Q1 2023 and a low of -$221000.0 during Q4 2021
  • For the 5-year period, Ekso Bionics Holdings' Depreciation and Depletion averaged around $163000.0, with its median value being $170000.0 (2022).
  • As far as peak fluctuations go, Ekso Bionics Holdings' Depreciation and Depletion surged by 45769.23% in 2020, and later tumbled by 24258.06% in 2021.
  • Ekso Bionics Holdings' Depreciation and Depletion (Quarter) stood at $171000.0 in 2019, then decreased by 9.36% to $155000.0 in 2020, then plummeted by 242.58% to -$221000.0 in 2021, then surged by 33.94% to -$146000.0 in 2022, then surged by 383.56% to $414000.0 in 2023.
  • Its Depreciation and Depletion stands at $414000.0 for Q1 2023, versus -$146000.0 for Q4 2022 and $170000.0 for Q3 2022.